Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells

Summary

Pulmonary vasodilators and prostacyclin therapy in particular, have markedly improved the outcome of patients with pulmonary hypertension (PH). Endothelial dysfunction is a key feature of PH, and we previously reported that treprostinil therapy increases number and proliferative potential of endothelial colony forming cells (ECFC) isolated from PH patients’ blood. In the present study, the objective was to determine how treprostinil contributes to the proangiogenic functions of ECFC. We examined the effect of treprostinil on ECFC obtained from cord blood in terms of colony numbers, proliferative and clonogenic properties in vitro, as well as in vivo vasculogenic properties. Surprisingly, treprostinil inhibited viability of cultured ECFC but did not modify their clonogenic properties or the endothelial differentiation potential from cord blood stem cells. Treprostinil treatment significantly increased the vessel-forming ability of ECFC combined with mesenchymal stem cells (MSC) in Matrigel implanted in nude mice. In vitro, ECFC proliferation was stimulated by conditioned media from treprostinil-pretreated MSC, and this effect was inhibited either by the use of VEGF-A blocking antibodies or siRNA VEGF-A in MSC. Silencing VEGF-A gene in MSC also blocked the pro-angiogenic effect of treprostinil in vivo. In conclusion, increased VEGF-A produced by MSC can account for the increased vessel formation observed during treprostinil treatment. The clinical relevance of these data was confirmed by the high level of VEGF-A detected in plasma from patients with paediatric PH who had been treated with treprostinil. Moreover, our results suggest that VEGF-A level in patients could be a surrogate biomarker of treprostinil efficacy.

Keywords

Stem cells - vascular remodelling - vasculogenesis - endothelial progenitor cells - prostacyclin analogues

• References

• 1 Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331.
• 2 Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007; 82: 109-118.
• 3 Xiao CY, Hara A, Yuhki K. et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001; 104: 2210-2215.
• 4 Ghonem N, Yoshida J, Stolz DB. et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant 2011; 11: 2508-2516.
• 5 Murata T, Ushikubi F, Matsuoka T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-682.
• 6 Doi Y, Minami T, Nishizawa M. et al. Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. Neuroreport 2002; 13: 93-96.
• 7 Yung D, Widlitz AC, Rosenzweig EB. et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
• 8 Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
• 9 Levy M, Celermajer DS, Bourges-Petit E. et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011; 158: 584-588.
• 10 Levy M, Bonnet D, Mauge L. et al. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. PLoS One 2013; 8: e65114.
• 11 Smadja DM, Mauge L, Gaussem P. et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 2011; 14: 17-27.
• 12 Wang XX, Zhang FR, Shang YP. et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007; 49: 1566-1571.
• 13 Zhu JH, Wang XX, Zhang FR. et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 2008; 12: 650-655.
• 14 Yoder MC, Mead LE, Prater D. et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-1809.
• 15 Melero-Martin JM, De Obaldia ME, Kang SY. et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 2008; 103: 194-202.
• 16 Toshner M, Voswinckel R, Southwood M. et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 180: 780-787.
• 17 Baker CD, Seedorf GJ, Wisniewski BL. et al. Endothelial colony-forming cell conditioned media promote angiogenesis in vitro and prevent pulmonary hypertension in experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2013; 305: L73-81.
• 18 Melero-Martin JM, Bischoff J. Chapter 13. An in vivo experimental model for postnatal vasculogenesis. Methods Enzymol 2008; 445: 303-329.
• 19 Smadja DM, d’Audigier C, Bieche I. et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 2011; 31: 551-559.
• 20 Smadja DM, Mulliken JB, Bischoff J. E-selectin mediates stem cell adhesion and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2012; 181: 2239-2247.
• 21 Smadja DM, Guerin CL, Boscolo E. et al. alpha6-Integrin is required for the adhesion and vasculogenic potential of hemangioma stem cells. Stem Cells 2014; 32: 684-693.
• 22 Smadja D, Gaussem P, Roncal C. et al. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus 2010; 19: 837-843.
• 23 He T, Lu T, d’Uscio LV. et al. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 2008; 103: 80-88.
• 24 Kawabe J, Yuhki K, Okada M. et al. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodelling. Arterioscler Thromb Vasc Biol 2010; 30: 464-470.
• 25 Smadja DM, Gaussem P, Mauge L. et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009; 119: 374-381.
• 26 Smadja DM, Mauge L, Sanchez O. et al. Distinct patterns of circulating endothelial cells in pulmonary hypertension. Eur Respir J 2010; 36: 1284-1293.
• 27 Mauge L, Sabatier F, Boutouyrie P. et al. Forearm ischemia decreases endothelial colony-forming cell angiogenic potential. Cytotherapy 2014; 16: 213-224.
• 28 Ingram DA, Mead LE, Moore DB. et al. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005; 105: 2783-2786.
• 29 Alvarez DF, Huang L, King JA. et al. Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity. Am J Physiol Lung Cell Mol Physiol 2008; 294: L419-430.
• 30 Hur J, Yoon CH, Kim HS. et al. Characterisation of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-293.
• 31 Kang KT, Coggins M, Xiao C. et al. Human vasculogenic cells form functional blood vessels and mitigate adverse remodelling after ischemia reperfusion injury in rats. Angiogenesis 2013; 16: 773-784.
• 32 Tan K, Lessieur E, Cutler A. et al. Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy. Exp Eye Res 2010; 91: 229-237.
• 33 Smadja DM, Mauge L, Nunes H. et al. Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis 2013; 16: 147-157.
• 34 Duong HT, Comhair SA, Aldred MA. et al. Pulmonary artery endothelium resident endothelial colony-forming cells in pulmonary arterial hypertension. Pulm Circ 2011; 1: 475-486.
• 35 Clapp LH, Finney P, Turcato S. et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
• 36 Ali FY, Egan K, FitzGerald GA. et al. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2006; 34: 242-246.
• 37 Nikam VS, Schermuly RT, Dumitrascu R. et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J 2010; 36: 1302-1314.
• 38 Nikam VS, Wecker G, Schermuly R. et al. Treprostinil Inhibits the Adhesion and Differentiation of Fibrocytes via the Cyclic Adenosine Monophosphate-Dependent and Ras-Proximate Protein-Dependent Inactivation of Extracellular Regulated Kinase. Am J Respir Cell Mol Biol 2011; 45: 692-703.
• 39 Liu Q, Xi Y, Terry T. et al. Engineered endothelial progenitor cells that overex-press prostacyclin protect vascular cells. J Cell Physiol 2012; 227: 2907-2916.
• 40 Di Stefano R, Barsotti MC, Melillo E. et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-877.
• 41 Song Y. Association study of circulating endothelial progenitor cells and plasma prostacyclin levels in pulmonary hypertension rats. Genet Mol Res 2014; 13: 438-444.
• 42 Asahara T, Takahashi T, Masuda H. et al. VEGF contributes to postnatal neovascularisation by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999; 18: 3964-3972.
• 43 Eddahibi S, Humbert M, Sediame S. et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162: 1493-1499.
• 44 Smadja DM, Laurendeau I, Avignon C. et al. The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. J Thromb Haemost 2006; 4: 2051-2058.
• 45 Mata-Greenwood E, Meyrick B, Soifer SJ. et al. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003; 285: L222-231.
• 46 Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-2694.
• 47 d’Audigier C, Gautier B, Yon A. et al. Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. Angiogenesis 2014; 17: 603-616.
• 48 Smadja DM, Bieche I, Helley D. et al. Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6). J Cell Mol Med 2007; 11: 1149-1161.
• 49 Sakao S, Tatsumi K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 2010; 81: 253-261.
• 50 Kamio K, Sato T, Liu X. et al. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1226-1232.
• 51 Pola R, Gaetani E, Flex A. et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36: 363-370.
• 52 Park DW, Baek K, Lee JG. et al. Activation of toll-like receptor 4 modulates vascular endothelial growth factor synthesis through prostacyclin-IP signaling. Biochem Biophys Res Commun 2007; 362: 1090-1095.
• 53 Biscetti F, Gaetani E, Flex A. et al. Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J Vasc Res 2009; 46: 103-108.
• 54 Moncada S, Gryglewski R, Bunting S. et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
• 55 Varol E, Uysal BA, Ozaydin M. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost 2011; 17: E171-174.
• 56 Nadaud S, Poirier O, Girerd B. et al. Small platelet microparticle levels are increased in pulmonary arterial hypertension. Eur J Clin Invest 2013; 43: 64-71.
• 57 Levy M, Maurey C, Celermajer DS. et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007; 49: 803-810.
• 58 Nana-Sinkam SP, Lee JD, Sotto-Santiago S. et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 2007; 175: 676-685.